Abstract
The metabolic syndrome is strongly associated with insulin resistance and visceral obesity and consists of a constellation of factors such as diabetes, hypertension, dyslipidemia and non-alcoholic steatohepatits, which could in concert increase the risk for cardiovascular diseases (CVD). CVD, including myocardial infarction and stroke, is one of the leading causes of morbidity and mortality in the developed countries. Atherothrombosis, characterized by atherosclerotic plaque disruption and subsequent thrombus formation, contributes to the pathogenesis of CVD. Although therapeutic strategy for CVD has been progressed with anti-platelet and anti-thrombotic therapy, statins, and inhibitors of renin-angiotensin system, current therapeutic options may have therapeutic limitations because a substantial number of patients still experience CVD. Therefore, to develop novel therapeutic strategies that specifically target CVD is intensely desired. We and the others, have recently found that pigment epithelium-derived factor (PEDF), one of the serpins with neuronal differentiative activity, has insulin-sensitizing actions in the liver and adipose tissues, and exerts anti-inflammatory, anti-thrombogenic and vasculoprotective properties in vivo, thereby playing a protective role against the development and progression of the metabolic syndrome and CVD. In addition, serum levels of PEDF have been shown to increase in patients with visceral obesity, insulin resistance, diabetes, chronic kidney disease and CVD, thus being a novel biomarker of various cardiometabolic disorders. This paper discusses not only the role of PEDF, but also the clinical utility of measuring its levels in patients with various cardiometabolic disorders.
Keywords: Atherosclerosis, cardiometabolic disorders, oxidative stress, PEDF.
Current Pharmaceutical Design
Title:Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Volume: 20 Issue: 14
Author(s): Sho-ichi Yamagishi and Takanori Matsui
Affiliation:
Keywords: Atherosclerosis, cardiometabolic disorders, oxidative stress, PEDF.
Abstract: The metabolic syndrome is strongly associated with insulin resistance and visceral obesity and consists of a constellation of factors such as diabetes, hypertension, dyslipidemia and non-alcoholic steatohepatits, which could in concert increase the risk for cardiovascular diseases (CVD). CVD, including myocardial infarction and stroke, is one of the leading causes of morbidity and mortality in the developed countries. Atherothrombosis, characterized by atherosclerotic plaque disruption and subsequent thrombus formation, contributes to the pathogenesis of CVD. Although therapeutic strategy for CVD has been progressed with anti-platelet and anti-thrombotic therapy, statins, and inhibitors of renin-angiotensin system, current therapeutic options may have therapeutic limitations because a substantial number of patients still experience CVD. Therefore, to develop novel therapeutic strategies that specifically target CVD is intensely desired. We and the others, have recently found that pigment epithelium-derived factor (PEDF), one of the serpins with neuronal differentiative activity, has insulin-sensitizing actions in the liver and adipose tissues, and exerts anti-inflammatory, anti-thrombogenic and vasculoprotective properties in vivo, thereby playing a protective role against the development and progression of the metabolic syndrome and CVD. In addition, serum levels of PEDF have been shown to increase in patients with visceral obesity, insulin resistance, diabetes, chronic kidney disease and CVD, thus being a novel biomarker of various cardiometabolic disorders. This paper discusses not only the role of PEDF, but also the clinical utility of measuring its levels in patients with various cardiometabolic disorders.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi and Matsui Takanori, Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990473
DOI https://dx.doi.org/10.2174/13816128113199990473 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics Multifactorial Regulation of GPER Expression in Cancer Cells and Cardiomyocytes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nosocomial Infections and Antimicrobial Treatment in Coiled Patients with Aneurysmal Subarachnoid Hemorrhage
Current Drug Targets Chronic Obstructive Pulmonary Disease and Oxidative Stress
Current Pharmaceutical Biotechnology Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets Regulation of Cardiac Nerves: A New Paradigm in The Management of Sudden Cardiac Death?
Current Medicinal Chemistry Clinical Assessment of Central Blood Pressure
Current Hypertension Reviews Antiinflammatory Activities of CGRP Modulating Innate Immune Responses in Health and Disease
Current Protein & Peptide Science Prevalence of Analgesic Use and Pain in People with and without Dementia or Cognitive Impairment in Aged Care Facilities: A Systematic Review and Meta-Analysis
Current Clinical Pharmacology Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Cost of Atrial Fibrillation: Invasive vs Non-Invasive Management in 2012
Current Cardiology Reviews Purification and Kinetics of Bovine Kidney Cortex Glutathione Reductase
Protein & Peptide Letters The Plasma and Tissue Kininogen-kallikrein-kinin System: Role in the Cardiovascular System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Targeting Vascular Redox Biology Through Antioxidant Gene Delivery: A Historical View and Current Perspectives
Recent Patents on Cardiovascular Drug Discovery Pathogenesis of the Podocytopathy and Proteinuria in Diabetic Glomerulopathy
Current Diabetes Reviews Alpha-2 Agonists: Can they Modify the Outcomes in the Postanesthesia Care Unit?
Current Drug Targets Telmisartan Promotes Potential Glucose Homeostasis in Stroke-Resistant Spontaneously Hypertensive Rats via Peroxisome Proliferator-Activated Receptor γ Activation
Current Neurovascular Research Tobacco Smoking and Association between Betel Nut Chewing and Metabolic Abnormalities Among Military Males: The CHIEF Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs
Current Pharmaceutical Design Nitric Oxide in the Dorsal Medulla Modulates Excitatory Somatosympathetic Reflexes
Current Cardiology Reviews